Global brokerage firm UBS has initiated coverage on several pharma stocks, highlighting potential upsides and challenges within the sector. The report points to weakening trends in both India and the US, with underappreciated growth slowdowns in these markets. UBS has provided a mixed outlook, issuing both ‘Buy’ and ‘Sell’ ratings on a range of pharmaceutical stocks.Here is a list of 6 pharma stocks on which UBS initiated coverage:
Sebi board meeting: Regulator eases IPO rules for start-up founders, mandates dematerialisation of securities
SEBI has relaxed ESOP rules for startup founders, allowing them to retain or exercise share-based benefits post-listing, provided they received them at least a year
June 18, 2025